3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
106
Fallopian Tube Neoplasms
48
Carcinoma, Ovarian Epithelial
31
Uterine Cervical Neoplasms
28
Pancreatic Neoplasms
13
Endometrial Neoplasms
13
Neoplasms
10
Colorectal Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
10
Recurrence
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Lung Neoplasms
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Sarcoma
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Peritoneal Neoplasms
5
Cholangiocarcinoma
5
Small Cell Lung Carcinoma
4
Melanoma
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Colonic Neoplasms
4
Vulvar Neoplasms
3
Uterine Neoplasms
3
Multiple Myeloma
3
Carcinoma
3
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gemcitabine
×
Gynecologic
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled